Key clinical point: Patients with upper gastrointestinal disease (UGID) receiving proton pump inhibitors (PPI) showed a dose-dependent increased risk for type 2 diabetes (T2D) compared with those not receiving PPI.
Major finding: The risk for T2D was significantly higher in patients receiving a cumulative defined daily dose (cDDD) of PPI of 31-120 mg (adjusted odds ratio [aOR] 1.20, 95% CI 1.13-1.26), 121-365 mg (aOR 1.26; 95% CI 1.19-1.33), and >365 mg (aOR 1.34; 95% CI 1.23-1.46) than in those receiving a cDDD of PPI ≤30 mg.
Study details: Findings are from a nested case-control study including 41,880 patients with UGID who received PPI, of which 20,940 who subsequently developed T2D were matched with 20,940 who did not develop T2D.
Disclosures: This study was supported by grants from Taipei Veterans General Hospital, Taiwan, and others. The authors declared no conflicts of interest.
Source: Kuo HY et al. Dose-dependent proton pump inhibitor exposure and risk of type 2 diabetes: A nationwide nested case–control study. Int J Environ Res Public Health. 2022;19(14):8739 (Jul 18). Doi: 10.3390/ijerph19148739